Published in Arterioscler Thromb Vasc Biol on May 20, 2004
Change in prostaglandin expression levels and synthesizing activities in dry eye disease. Ophthalmology (2012) 2.07
Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev (2011) 1.67
Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli. Am J Physiol Heart Circ Physiol (2010) 1.46
Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis. J Clin Invest (2009) 1.12
Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results. Stroke (2012) 1.11
Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. PLoS One (2010) 1.08
Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med (2007) 1.07
Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation (2010) 1.04
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br J Pharmacol (2009) 0.99
Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol (2006) 0.94
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther (2007) 0.92
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis (2007) 0.89
Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study. Atherosclerosis (2008) 0.87
Dihydrotestosterone alters cyclooxygenase-2 levels in human coronary artery smooth muscle cells. Am J Physiol Endocrinol Metab (2010) 0.86
The transcriptome of human epicardial, mediastinal and subcutaneous adipose tissues in men with coronary artery disease. PLoS One (2011) 0.84
Resolution of Inflammation: What Controls Its Onset? Front Immunol (2016) 0.84
Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Res Ther (2008) 0.82
Cognitive outcome and cyclo-oxygenase-2 gene (-765 G/C) variation in the preterm infant. Arch Dis Child Fetal Neonatal Ed (2006) 0.81
Nrf2 is essential for the expression of lipocalin-prostaglandin D synthase induced by prostaglandin D2. Free Radic Biol Med (2013) 0.80
A potential therapeutic effect of CYP2C8 overexpression on anti-TNF-α activity. Int J Mol Med (2014) 0.80
Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary. Stroke (2006) 0.79
Cyclooxygenase products and atherosclerosis. Drug Discov Today Ther Strateg (2008) 0.79
Decreased PGE₂ content reduces MMP-1 activity and consequently increases collagen density in human varicose vein. PLoS One (2014) 0.78
Research Progress on the Risk Factors and Outcomes of Human Carotid Atherosclerotic Plaques. Chin Med J (Engl) (2017) 0.75
Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. Clin Med Insights Cardiol (2011) 0.75
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens (2005) 4.19
Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care (2007) 2.96
Platelet activation in obese women: role of inflammation and oxidant stress. JAMA (2002) 2.79
(In)accuracy of blood pressure measurement in 14 Italian hospitals. J Hypertens (2012) 2.76
Childhood obesity. J Clin Endocrinol Metab (2004) 2.29
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Viscero-visceral hyperalgesia: characterization in different clinical models. Pain (2010) 2.07
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med (2012) 2.01
Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis (2002) 1.98
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med (2007) 1.88
Acute effects of air pollution on pulmonary function, airway inflammation, and oxidative stress in asthmatic children. Environ Health Perspect (2008) 1.83
New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care (2009) 1.74
Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab (2010) 1.73
Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab (2007) 1.72
Obese related effects of inflammatory markers and insulin resistance on increased carotid intima media thickness in pre-pubertal children. Atherosclerosis (2007) 1.68
Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med (2007) 1.67
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. Stroke (2010) 1.67
Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens (2009) 1.59
Treatment of diabetic ketoacidosis in children and adolescents. Acta Biomed (2003) 1.59
Variables associated with severe hypoglycemia in children and adolescents with type 1 diabetes: a population-based study. Pediatr Diabetes (2010) 1.59
Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke (2004) 1.57
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
Screening of metabolic syndrome in obese children: a primary care concern. J Pediatr Gastroenterol Nutr (2009) 1.55
Ambulatory blood pressure monitoring in obese children: role of insulin resistance. J Hypertens (2006) 1.51
Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens (2010) 1.49
Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol (2002) 1.48
Epicardial adipose tissue and metabolic syndrome in hypertensive patients with normal body weight and waist circumference. Am J Hypertens (2011) 1.48
Long-term follow-up of children treated for acute lymphoblastic leukemia and the recovery of beta-cell function. Haematologica (2006) 1.48
Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia (2002) 1.46
Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens (2008) 1.45
Efficacy of an interleukin-1β receptor antagonist (anakinra) in idiopathic recurrent pericarditis. Pediatr Cardiol (2012) 1.44
Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr (2002) 1.40
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA (2004) 1.40
Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens (2010) 1.39
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol (2003) 1.39
ISPAD Clinical Practice Consensus Guidelines 2006-2007. Microvascular and macrovascular complications. Pediatr Diabetes (2007) 1.39
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A (2002) 1.39
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol (2006) 1.38
Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes (2009) 1.37
Role of chronic and acute hyperglycemia in the development of diabetes complications. Diabetes Technol Ther (2011) 1.36
An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes (2007) 1.30
Soluble forms of RAGE in internal medicine. Intern Emerg Med (2009) 1.28
Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol (2011) 1.26
Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol (2007) 1.23
Prognostic relevance of masked hypertension in subjects with prehypertension. Am J Hypertens (2008) 1.17
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res (2003) 1.17
Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther (2008) 1.17
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation (2003) 1.16
Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am J Hypertens (2004) 1.16
Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett (2003) 1.15
Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol (2005) 1.15
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res (2012) 1.15
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15
Insulin resistance and oxidative stress in children born small and large for gestational age. Pediatrics (2009) 1.14
A prospective evaluation of iron deficiency anemia in the GI endoscopy setting: role of standard endoscopy, videocapsule endoscopy, and CT-enteroclysis. Gastrointest Endosc (2011) 1.11
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol (2006) 1.11
Telomere length and obesity. Acta Paediatr (2008) 1.10
Technology and the issue of cost/benefit in diabetes. Diabetes Metab Res Rev (2009) 1.10